We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Pioneering COVID-19 Testing Platform Combines Saliva-Based Sampling, Pooled Testing and PCR Diagnostics

By LabMedica International staff writers
Posted on 09 Mar 2021
A pioneering COVID-19 testing platform combines saliva-based sampling, pooled testing and PCR diagnostics to enable high-quality, high-throughput, low-cost detection of SARS-CoV-2.

Mirimus, Inc.’s (Brooklyn, NY, USA) SalivaClear platform is designed to provide a SARS-CoV-2 diagnostic system that can be easily and repeatedly utilized by myriad organizations, from schools to businesses to government organizations, to test (and retest) groups of individuals in order to quickly isolate COVID-19 hotspots before they can become outbreaks. More...
Mirimus has innovated high-volume COVID-19 PCR testing with SalivaClear, a three-stage surveillance and individual reflex testing strategy to monitor and detect infection in populations by testing people in groups called pools. All three-stages of testing are performed with only one self-collected saliva sample.

For collecting the sample, Mirimus uses a simple self-collection method that is composed of a 2 mL cryogenics vial and saliva collection aid (straw). The saliva straw fits into a cryogenic vial and the testing individual deposits 1 mL of saliva through the straw into the vial. 1 mL of saliva is required for pool testing, subpool testing, and individual diagnostic testing. The individual samples are then shipped to Mirimus' lab where they are pooled into groups of 24 and analyzed using the FDA Emergency Use Authorized ThermoFisherScientific TaqPathCOVID-19 Combo RT-PCR Kit. The pooled test results are typically reported within 24 hours of sample receipt at the laboratory. If a pool tests positive, it is split into 12 pools of two, which are re-tested at the laboratory. If a positive signal emerges from a two-sample pool, the two individuals are asked to provide consent for a final test to determine individual positivity. SalivaClear has been shown to substantially reduce the cost associated with PCR testing and allow schools to rapidly assess transmission and make data-driven decisions to adjust prevention protocols.

"Colleges and universities have, unfortunately, been associated with a substantial number of COVID-19 cases across the country, with a recent report from The New York Times suggesting that more than 120,000 COVID-19 cases have been linked to American colleges and universities since January 1st," said Prem Premsrirut, M.D., Ph.D., Co-founder and CEO of Mirimus. "Given this, the robust surveillance testing that SalivaClear provides is essential to ensuring a safe on-campus learning environment by enabling campus health administrators to quickly isolate hotspots before they can become outbreaks."

Related Links:
Mirimus, Inc.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.